Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations

Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung cancer and to co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESMO open 2022-12, Vol.7 (6), p.100742-100742, Article 100742
Hauptverfasser:	Wang, H.-Y., Wu, S.-G., Lin, Y.-T., Chen, C.-Y., Shih, J.-Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	ALK Anaplastic Lymphoma Kinase - genetics Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology EGFR ErbB Receptors - genetics Humans Lung Neoplasms - pathology Mutation non-small-cell lung cancer Original Research Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Retrospective Studies ROS1 rearrangement thromboembolism Thromboembolism - etiology Thromboembolism - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!